Literature DB >> 10203092

T-cell activation, proliferation, and memory after cardiac transplantation in vivo.

N D Jones1, A Van Maurik, M Hara, B J Gilot, P J Morris, K J Wood.   

Abstract

OBJECTIVE: To study the response of alloantigen (H2Kb)-specific T cells to a H2b+ cardiac allograft in vivo. SUMMARY BACKGROUND DATA: The response of T cells to alloantigen has been well characterized in vitro but has proved more difficult to assess in vivo. The aim of these experiments was to develop a model of T-cell-mediated rejection where the response of T cells after transplantation of a cardiac allograft could be followed in vivo.
METHODS: Purified CD8+ T cells from H2Kb-specific TCR transgenic mice (BM3; H2k) were adoptively transferred into thymectomized, T-cell-depleted CBA/Ca (H2k) mice. These mice were then transplanted with a H2Kb+ cardiac allograft. Using four-color flow cytometry, the proliferative response, modulation of activation markers, and potential cytokine production of the H2Kb-specific T cells was assessed after transplantation.
RESULTS: Consistent rejection of H2Kb+ cardiac allografts required the transfer of at least 6 x 10(6) CD8+ H2Kb-specific T cells. Short-term analyses revealed that the transgenic-TCR+/ CD8+ T cells proliferated and became activated after transplantation of an H2Kb+ cardiac allograft. Fifty days after transplantation, the transgenic-TCR+/CD8+ T cells remained readily detectable, bore a predominantly memory phenotype (CD44hi), and rapidly produced interleukin 2 and interferon-gamma on in vitro restimulation.
CONCLUSIONS: These data show that the activation of alloantigen-specific T cells can be followed in vivo in short-term and long-term experiments, thereby providing a unique opportunity to study the mechanisms by which T cells respond to allografts in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10203092      PMCID: PMC1191745          DOI: 10.1097/00000658-199904000-00018

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

Review 1.  Differential function of major histocompatibility complex antigens in T-lymphocyte activation.

Authors:  F H Bach; M L Bach; P M Sondel
Journal:  Nature       Date:  1976-01-29       Impact factor: 49.962

2.  Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor.

Authors:  R M Kedl; M F Mescher
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

3.  Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection.

Authors:  R J Corry; H J Winn; P S Russell
Journal:  Transplantation       Date:  1973-10       Impact factor: 4.939

4.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.

Authors:  S P Cobbold; A Jayasuriya; A Nash; T D Prospero; H Waldmann
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

Review 5.  T cell subsets and the recognition of MHC class.

Authors:  S L Swain
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

Review 6.  Which T cells cause graft rejection?

Authors:  B E Loveland; I F McKenzie
Journal:  Transplantation       Date:  1982-03       Impact factor: 4.939

Review 7.  Role of thymus-derived and thymus-independent cells in murine skin allograft rejection.

Authors:  M J Dallman; D W Mason
Journal:  Transplantation       Date:  1982-03       Impact factor: 4.939

8.  In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes.

Authors:  B T Rouse; H Wagner; A W Harris
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

Review 9.  Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity.

Authors:  D P Dialynas; D B Wilde; P Marrack; A Pierres; K A Wall; W Havran; G Otten; M R Loken; M Pierres; J Kappler
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

10.  The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts.

Authors:  B M Hall; S Dorsch; B Roser
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  5 in total

1.  CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein.

Authors:  Sylvie Ferrari-Lacraz; Xin Xiao Zheng; Alberto Sanchez Fueyo; Wlodzimierz Maslinski; Thomas Moll; Terry B Strom
Journal:  Transplantation       Date:  2006-12-15       Impact factor: 4.939

Review 2.  Cardiac allograft vasculopathy: a donor or recipient induced pathology?

Authors:  Patricia van den Hoogen; Manon M H Huibers; Joost P G Sluijter; Roel A de Weger
Journal:  J Cardiovasc Transl Res       Date:  2015-02-05       Impact factor: 4.132

3.  The Transcription Factor NFATc1 Supports the Rejection of Heterotopic Heart Allografts.

Authors:  Johannes Baur; Christoph Otto; Ulrich Steger; Stefan Klein-Hessling; Khalid Muhammad; Tobias Pusch; Krisna Murti; Rhoda Wismer; Christoph-Thomas Germer; Ingo Klein; Nora Müller; Edgar Serfling; Andris Avots
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

4.  Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.

Authors:  R Goto; S You; M Zaitsu; L Chatenoud; K J Wood
Journal:  Am J Transplant       Date:  2013-06-10       Impact factor: 8.086

5.  Targeted Delivery of Immunomodulators to Lymph Nodes.

Authors:  Jamil Azzi; Qian Yin; Mayuko Uehara; Shunsuke Ohori; Li Tang; Kaimin Cai; Takaharu Ichimura; Martina McGrath; Omar Maarouf; Eirini Kefaloyianni; Scott Loughhead; Jarolim Petr; Qidi Sun; Mincheol Kwon; Stefan Tullius; Ulrich H von Andrian; Jianjun Cheng; Reza Abdi
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.